BrainChild Bio Raises $116 Million, Launches Pivotal DIPG CAR-T Trial

BrainChild Bio has closed a $116 million Series A financing round and simultaneously initiated its pivotal phase 2 ILLUMINATE trial evaluating BCB-276, an investigational B7-H3-targeted autologous chimeric antigen receptor T cell (CAR-T) therapy, in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG), the company announced September 8, 2026.¹,² The financing was led by an undisclosed private family fund and foundation, with participation from initial investor Seattle Children's and new investor WRF Capital, and will support the pivotal trial along with the company's earlier-stage pipeline.²

"This financing enables us to chart our path forward to serve the children and families afflicted with devastating brain tumors and represents a new paradigm for treating CNS [central nervous system] brain tumors in children and adults," said Michael Jensen, MD, founder and chief scientific officer of BrainChild Bio, in a company press release.² "Our team at BrainChild Bio is steadfast in its commitment to harness CAR T cell technology in CNS tumors and we are uniquely positioned to do so."

What will the pivotal ILLUMINATE trial evaluate?

The ILLUMINATE trial (NCT07680439) is an open-label, single-arm, pivotal phase 2 registrational study evaluating BCB-276 in children and young adults with newly diagnosed DIPG following standard-of-care focal radiation therapy, with a design aligned with the FDA to support a future biologics license application. The trial's primary endpoint is overall survival, with safety, tolerability, progression-free survival, and radiographic response as secondary endpoints.¹

Patients will receive BCB-276 approximately every 2 weeks for up to 15 doses over approximately 7 to 8 months, administered by locoregional delivery directly into the cerebrospinal fluid using an indwelling reservoir-catheter device. The trial will enroll patients at 6 leading pediatric neuro-oncology centers across the United States, and BCB-276 has received FDA fast track designation.¹

What evidence supports BCB-276's advancement to a pivotal trial?

BCB-276 is based on a CAR-T therapy Dr Jensen and colleagues developed at Seattle Children's, exclusively licensed to BrainChild Bio.¹ In an earlier BrainChild-03 phase 1 trial (NCT04185038), 21 patients with DIPG received a total of 253 intracerebroventricular CAR-T cell doses. Median survival from initial CAR T cell infusion was 10.7 months, median survival from diagnosis was 19.8 months, and 3 patients remained alive at 44, 45, and 52 months from diagnosis, with 1 dose-limiting toxicity reported.³ By comparison, current standard-of-care focal radiation therapy alone results in a median overall survival of only about 11 months from diagnosis.¹

Why is a new treatment needed for DIPG?

DIPG is a uniformly fatal high-grade brain tumor arising in the brainstem, affecting approximately 300 children per year in the US, most commonly diagnosed between ages 5 and 10.¹ Treatment has historically been limited by the tumor's brainstem location, infiltrative growth, and the blood-brain barrier, which remains relatively intact during tumor progression. The company's locoregional cerebrospinal fluid delivery approach is designed to let CAR T cells directly access the tumor while minimizing off-tumor toxicity.¹

"Children and families facing a diagnosis of DIPG urgently need new treatment options," said Cori Abikoff, MD, vice president of clinical development at BrainChild Bio, in a company press release.¹ "The pivotal Phase 2 ILLUMINATE study represents an important step in evaluating the potential of BCB-276 for children with newly diagnosed DIPG."

What's next for BrainChild Bio's pipeline and what are the limitations?

Beyond BCB-276, Series A proceeds will also support continued development of BCB-214, the company's triple-targeting CAR-T therapy being advanced toward initial clinical testing in glioblastoma, part of BrainChild Bio's broader strategy to expand from pediatric into adult CNS tumors.²

The BrainChild-03 phase 1 data supporting BCB-276's advancement come from a single-center, dose-escalation trial without a randomized control arm, and cross-trial comparisons with historical survival data should be interpreted cautiously. The ILLUMINATE trial is open-label and single-arm rather than randomized and controlled. Financial terms of the Series A beyond the total amount raised were not disclosed.

References

1. BrainChild Bio. BrainChild Bio initiates pivotal Phase 2 trial for BCB-276 CAR T cell therapy for DIPG, a deadly pediatric brain cancer. Press release. Published September 8, 2026. Accessed September 8, 2026. https://brainchildbio.com/wp-content/uploads/2026/09/BCBio_Phase2InitiationPR_FINAL_09-08-26.pdf
2. BrainChild Bio. BrainChild Bio closes $116 million Series A financing. Press release. Published September 8, 2026. Accessed September 8, 2026. https://brainchildbio.com/wp-content/uploads/2026/09/BCBio_SeriesA_PR_FINAL_09-08-26.pdf
3. Vitanza NA, Ronsley R, Choe M, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025;31(3):861-868. doi:10.1038/s41591-024-03451-3